EKF Diagnostics Holdings plc
("EKF" or the "Company")
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2022 ("2022 Annual Report") and the Notice of the 2023 Annual General Meeting ("AGM") have now been published on the Company's website:
https://www.ekfdiagnostics.com/documents-reports.html
The 2022 Annual Report, the Notice of AGM and details for voting by proxy will be posted today to shareholders who have not consented to receive electronic communications.
The AGM is to be held at 10:30 am on 17 May 2023 at 6 Stratton Street Mayfair, London W1J 8LD and will consider the Resolutions set out in the Notice of AGM.
The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 10:30 am on 15 May 2023. To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8780.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the 2023 AGM in the post. Instead, shareholders will be able to vote electronically using the link available via https://www.signalshares.com and selecting the "Proxy Voting" link or lodging a proxy appointment by using the CREST Proxy Voting Service.
Alternatively, shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0391. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.
|
EKF Diagnostics Holdings plc |
|||
|
Julian Baines, Executive Chair / Marc Davies, CFO |
Tel: +44 (0)29 2071 0570 |
||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Aubrey Powell / George Tzimas / Oliver Platts |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Lianne Applegarth |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.